Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1992;1(3):151–165. doi: 10.1155/S0962935192000243

Mechanism of action of 5-arninosalicylic acid

N A Punchard 1,✉, S M Greenfield 1, R P H Thompson 1
PMCID: PMC2365334  PMID: 18475455

Abstract

5-Aminosalicylic Acid (5-ASA) has been used for over 50 years in the treatment of inflammatory bowel disease in the pro-drug form sulphasalazine (SASP). SASP is also used to treat rheumatoid arthritis. However whether the therapeutic properties of SASP are due to the intact molecule, the 5-ASA or sulphapyridine components is unknown. Several mechanisms of action have been proposed for 5-ASA and SASP including interference in the metabolism of arachidonic acid to prostaglandins and leukotrienes, scavenging,of reactive oxygen species, effects on leucocyte function and production of cytokines. However, it is unlikely that the anti-inflammatory properties of SASP and 5-ASA are due to several different properties but more likely that a single property of 5-ASA explains the theraapeutic effects of 5-ASA and SASP. Reactive oxygen species (ROS) are involved in the metabolism of prostaglandins and leukotrienes and can act as second messengers, and so the scavenging of ROS may be the single mechanism of action of 5-ASA that gives rise to its antiinflammatory effects in both inflammatory bowel disease and rheumatoid arthritis.

Full Text

The Full Text of this article is available as a PDF (1.7 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahnfelt-Rønne I., Nielsen O. H., Bukhave K., Elmgreen J. Sulfasalazine and its anti-inflammatory metabolite, 5-aminosalicylic acid: effect on arachidonic acid metabolism in human neutrophils, and free radical scavenging. Adv Prostaglandin Thromboxane Leukot Res. 1987;17B:918–922. [PubMed] [Google Scholar]
  2. Ahnfelt-Rønne I., Nielsen O. H., Christensen A., Langholz E., Binder V., Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology. 1990 May;98(5 Pt 1):1162–1169. doi: 10.1016/0016-5085(90)90329-y. [DOI] [PubMed] [Google Scholar]
  3. Ahnfelt-Rønne I., Nielsen O. H. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions. 1987 Jun;21(1-2):191–194. doi: 10.1007/BF01974941. [DOI] [PubMed] [Google Scholar]
  4. Ali A. T., Basran G. S., Morley J. Mode of action of sulphasalazine: an alternative view. Lancet. 1982 Feb 27;1(8270):506–507. doi: 10.1016/s0140-6736(82)91474-x. [DOI] [PubMed] [Google Scholar]
  5. Allgayer H., Deschryver K., Stenson W. F. Treatment with 16,16'-dimethyl prostaglandin E2 before and after induction of colitis with trinitrobenzenesulfonic acid in rats decreases inflammation. Gastroenterology. 1989 May;96(5 Pt 1):1290–1300. doi: 10.1016/s0016-5085(89)80016-2. [DOI] [PubMed] [Google Scholar]
  6. Allgayer H., Eisenburg J., Paumgartner G. Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449–451. doi: 10.1007/BF00542139. [DOI] [PubMed] [Google Scholar]
  7. Aparicio-Pagés M. N., Verspaget H. W., Hafkenscheid J. C., Crama-Bohbouth G. E., Peña A. S., Weterman I. T., Lamers H. W. Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity. Gut. 1990 Sep;31(9):1030–1032. doi: 10.1136/gut.31.9.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Aruoma O. I., Halliwell B. The iron-binding and hydroxyl radical scavenging action of anti-inflammatory drugs. Xenobiotica. 1988 Apr;18(4):459–470. doi: 10.3109/00498258809041682. [DOI] [PubMed] [Google Scholar]
  9. Aruoma O. I., Wasil M., Halliwell B., Hoey B. M., Butler J. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? Biochem Pharmacol. 1987 Nov 1;36(21):3739–3742. doi: 10.1016/0006-2952(87)90028-1. [DOI] [PubMed] [Google Scholar]
  10. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  11. BARGEN J. A. Treatment of ulcerative colitis with salicylazosulfapyridine (salazopyrin). Med Clin North Am. 1949 Jul;33:935–942. doi: 10.1016/s0025-7125(16)35528-6. [DOI] [PubMed] [Google Scholar]
  12. BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
  13. Bach M. K., Brashler J. R., Johnson M. A. Inhibition by sulfasalazine of LTC synthetase and of rat liver glutathione S-transferases. Biochem Pharmacol. 1985 Aug 1;34(15):2695–2704. doi: 10.1016/0006-2952(85)90570-2. [DOI] [PubMed] [Google Scholar]
  14. Barrett K. E., Tashof T. L., Metcalfe D. D. Inhibition of IgE-mediated mast cell degranulation by sulphasalazine. Eur J Pharmacol. 1985 Jan 2;107(2):279–281. doi: 10.1016/0014-2999(85)90071-8. [DOI] [PubMed] [Google Scholar]
  15. Baum C. L., Selhub J., Rosenberg I. H. Antifolate actions of sulfasalazine on intact lymphocytes. J Lab Clin Med. 1981 Jun;97(6):779–784. [PubMed] [Google Scholar]
  16. Berry C. N., Hoult J. R., Peers S. H., Agback H. Inhibition of prostaglandin 15-hydroxydehydrogenase by sulphasalazine and a novel series of potent analogues. Biochem Pharmacol. 1983 Oct 1;32(19):2863–2871. doi: 10.1016/0006-2952(83)90390-8. [DOI] [PubMed] [Google Scholar]
  17. Blackwell G. J., Flower R. J., Vane J. R. Some characteristics of the prostaglandin synthesizing system in rabbit kidney microsomes. Biochim Biophys Acta. 1975 Jul 22;398(1):178–190. doi: 10.1016/0005-2760(75)90181-2. [DOI] [PubMed] [Google Scholar]
  18. Campieri M., Lanfranchi G. A., Bazzocchi G., Brignola C., Sarti F., Franzin G., Battocchia A., Labo G., Dal Monte P. R. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981 Aug 8;2(8241):270–271. doi: 10.1016/s0140-6736(81)90523-7. [DOI] [PubMed] [Google Scholar]
  19. Campieri M., Lanfranchi G. A., Bazzocehi G., Brignola C., Corazza G., Cortini C., Michelini M., Labó G. Salicylate other than 5-aminosalicylic acid ineffective in ulcerative colitis. Lancet. 1978 Nov 4;2(8097):993–993. doi: 10.1016/s0140-6736(78)92556-4. [DOI] [PubMed] [Google Scholar]
  20. Carpenter M. P. Antioxidant effects on the prostaglandin endoperoxide synthetase product profile. Fed Proc. 1981 Feb;40(2):189–194. [PubMed] [Google Scholar]
  21. Collier H. O., Francis A. A., McDonald-Gibson W. J., Saeed S. A. Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites. Prostaglandins. 1976 Feb;11(2):219–225. doi: 10.1016/0090-6980(76)90145-3. [DOI] [PubMed] [Google Scholar]
  22. Comer S. S., Jasin H. E. In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol. 1988 Apr;15(4):580–586. [PubMed] [Google Scholar]
  23. Craven P. A., Pfanstiel J., Saito R., DeRubertis F. R. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology. 1987 Jun;92(6):1998–2008. doi: 10.1016/0016-5085(87)90635-4. [DOI] [PubMed] [Google Scholar]
  24. Crotty B., Hoang P., Dalton H. R., Jewell D. P. Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression. Gut. 1992 Jan;33(1):59–64. doi: 10.1136/gut.33.1.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Dallegri F., Ottonello L., Ballestrero A., Bogliolo F., Ferrando F., Patrone F. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut. 1990 Feb;31(2):184–186. doi: 10.1136/gut.31.2.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Deckmyn H., Zoja C., Arnout J., Todisco A., Vanden Bulcke F., D'Hondt L., Hendrickx N., Gresele P., Vermylen J. Partial isolation and function of the prostacyclin regulating plasma factor. Clin Sci (Lond) 1985 Oct;69(4):383–393. doi: 10.1042/cs0690383. [DOI] [PubMed] [Google Scholar]
  27. Del Soldato P., Campieri M., Brignola C., Bazzocchi G., Gionchetti P., Lanfranchi G. A., Tamba M. A possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: interaction with oxygen free radicals. Gastroenterology. 1985 Nov;89(5):1215–1216. doi: 10.1016/0016-5085(85)90251-3. [DOI] [PubMed] [Google Scholar]
  28. Dreyling K. W., Hoppe U., Peskar B. A., Schaarschmidt K., Peskar B. M. Leukotrienes in Crohn's disease: effect of sulfasalazine and 5-aminosalicylic acid. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:339–343. [PubMed] [Google Scholar]
  29. Dull B. J., Salata K., Van Langenhove A., Goldman P. 5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochem Pharmacol. 1987 Aug 1;36(15):2467–2472. doi: 10.1016/0006-2952(87)90518-1. [DOI] [PubMed] [Google Scholar]
  30. Eliakim R., Karmeli F., Razin E., Rachmilewitz D. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology. 1988 Nov;95(5):1167–1172. doi: 10.1016/0016-5085(88)90346-0. [DOI] [PubMed] [Google Scholar]
  31. Elitsur Y., Freedland C. P., Luk G. D. Inhibition of DNA synthesis in human peripheral and lamina propria lymphocytes by 5-aminosalicylic acid and hydrocortisone. Reg Immunol. 1990 Jan-Feb;3(1):56–61. [PubMed] [Google Scholar]
  32. Gibson P. R., Jewell D. P. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis. Clin Sci (Lond) 1985 Aug;69(2):177–184. doi: 10.1042/cs0690177. [DOI] [PubMed] [Google Scholar]
  33. Gilat T., Ratan J., Rosen P., Peled Y. Prostaglandins and ulcerative colitis. Gastroenterology. 1979 May;76(5 Pt 1):1083–1083. [PubMed] [Google Scholar]
  34. Gould S. R. Assay of prostaglandin-like substances in faeces and their measurement in ulcerative colitis. Prostaglandins. 1976 Mar;11(3):489–497. doi: 10.1016/0090-6980(76)90095-2. [DOI] [PubMed] [Google Scholar]
  35. Gould S. R., Brash A. R., Conolly M. E., Lennard-Jones J. E. Studies of prostaglandins and sulphasalazine in ulcerative colitis. Prostaglandins Med. 1981 Feb;6(2):165–182. doi: 10.1016/0161-4630(81)90088-4. [DOI] [PubMed] [Google Scholar]
  36. Gould S. R. Letter: Prostaglandins, ulcerative colitis, and sulphasalazine. Lancet. 1975 Nov 15;2(7942):988–988. doi: 10.1016/s0140-6736(75)90414-6. [DOI] [PubMed] [Google Scholar]
  37. Greenfield S. M., Punchard N. A., Thompson R. P. Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid. Gut. 1991 Oct;32(10):1156–1159. doi: 10.1136/gut.32.10.1156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Grindulis K. A., McConkey B. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone. Ann Rheum Dis. 1984 Jun;43(3):398–401. doi: 10.1136/ard.43.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Gupta A. K., Ellis C. N., Siegel M. T., Duell E. A., Griffiths C. E., Hamilton T. A., Nickoloff B. J., Voorhees J. J. Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol. 1990 Apr;126(4):487–493. [PubMed] [Google Scholar]
  40. HANNGREN A., HANSSON E., SVARTZ N., ULLBERG S. Distribution and metabolism of salicyl-azo-sulfapyridine. II. A study with S35-salicyl-azo-sulfapyridine and S35-sulfapyridine. Acta Med Scand. 1963 Apr;173:391–399. doi: 10.1111/j.0954-6820.1963.tb17422.x. [DOI] [PubMed] [Google Scholar]
  41. Halliwell B. Sulphasalazine and oxidant scavenging in ulcerative colitis. Lancet. 1987 Sep 12;2(8559):635–635. doi: 10.1016/s0140-6736(87)93033-9. [DOI] [PubMed] [Google Scholar]
  42. Hallwell B. Free radical scavengers and inflammatory bowel disease. Gastroenterology. 1991 Sep;101(3):872–872. doi: 10.1016/0016-5085(91)90562-y. [DOI] [PubMed] [Google Scholar]
  43. Harris D. W., Smith P. R., Swan C. H. Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease. Gut. 1978 Oct;19(10):875–877. doi: 10.1136/gut.19.10.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Hawkey C. J., Boughton-Smith N. K., Whittle B. J. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci. 1985 Dec;30(12):1161–1165. doi: 10.1007/BF01314051. [DOI] [PubMed] [Google Scholar]
  45. Hawkey C. J., Karmeli F., Rachmilewitz D. Imbalance of prostacyclin and thromboxane synthesis in Crohn's disease. Gut. 1983 Oct;24(10):881–885. doi: 10.1136/gut.24.10.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Hawkey C. J., Lo Casto M. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut. 1983 Mar;24(3):213–217. doi: 10.1136/gut.24.3.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Hawkey C. J., Rampton D. S. Benoxaprofen in the treatment of active ulcerative colitis. Prostaglandins Leukot Med. 1983 Apr;10(4):405–409. doi: 10.1016/0262-1746(83)90052-5. [DOI] [PubMed] [Google Scholar]
  48. Hellewell P. G., Pearson J. D. Effect of sulphasalazine on pulmonary inactivation of prostaglandin F2 alpha in the pig. Br J Pharmacol. 1982 Jun;76(2):319–326. doi: 10.1111/j.1476-5381.1982.tb09223.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Hillier K., Mason P. J., Pacheco S., Smith C. L. Ulcerative colitis: effect of sulphasalazine, its metabolites and indomethacin on the ability of human colonic mucosa to metabolize prostaglandins in vitro. Br J Pharmacol. 1982 May;76(1):157–161. doi: 10.1111/j.1476-5381.1982.tb09201.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Holdstock G., Chastenay B. F., Krawitt E. L. Functional suppressor T cell activity in Crohn's disease and the effects of sulphasalazine. Clin Exp Immunol. 1982 Jun;48(3):619–624. [PMC free article] [PubMed] [Google Scholar]
  51. Holdstock G., Chastenay B. F., Krawitt E. L. Increased suppressor cell activity in inflammatory bowel disease. Gut. 1981 Dec;22(12):1025–1030. doi: 10.1136/gut.22.12.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Holmdahl R., Klareskog L., Rubin K., Björk J., Smedegård G., Jonsson R., Andersson M. Role of T lymphocytes in murine collagen induced arthritis. Agents Actions. 1986 Dec;19(5-6):295–305. doi: 10.1007/BF01971231. [DOI] [PubMed] [Google Scholar]
  53. Hoult J. R., Moore P. K. Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle. Br J Pharmacol. 1980 Apr;68(4):719–730. doi: 10.1111/j.1476-5381.1980.tb10865.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Hoult J. R., Page H. 5-Aminosalicylic acid, a co-factor for colonic prostacyclin synthesis? Lancet. 1981 Aug 1;2(8240):255–255. doi: 10.1016/s0140-6736(81)90502-x. [DOI] [PubMed] [Google Scholar]
  55. Jarabak J., Braithwaite S. S. Kinetic studies on a 15-hydroxyprostaglandin dehydrogenase from human placenta. Arch Biochem Biophys. 1976 Nov;177(1):245–254. doi: 10.1016/0003-9861(76)90434-3. [DOI] [PubMed] [Google Scholar]
  56. Jarabak J., Luncsford A., Berkowitz D. Substrate specificity of three prostaglandin dehydrogenases. Prostaglandins. 1983 Dec;26(6):849–868. doi: 10.1016/0090-6980(83)90149-1. [DOI] [PubMed] [Google Scholar]
  57. Kanerud L., Hafström I., Ringertz B. Effect of sulphasalazine and sulphapyridine on neutrophil superoxide production: role of cytosolic free calcium. Ann Rheum Dis. 1990 May;49(5):296–300. doi: 10.1136/ard.49.5.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Kent R. S., Diedrich S. L., Whorton A. R. Regulation of vascular prostaglandin synthesis by metabolites of arachidonic acid in perfused rabbit aorta. J Clin Invest. 1983 Aug;72(2):455–465. doi: 10.1172/JCI110993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Keshavarzian A., Morgan G., Sedghi S., Gordon J. H., Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut. 1990 Jul;31(7):786–790. doi: 10.1136/gut.31.7.786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
  61. Kolassa N., Becker R., Wiener H. Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa. Prostaglandins. 1985 Jan;29(1):133–142. doi: 10.1016/0090-6980(85)90158-3. [DOI] [PubMed] [Google Scholar]
  62. Korff J., Jarabak J. Partial isolation and characterization of the 15-hydroxyprostaglandin dehydrogenases and 9-ketoprostaglandin reductases in rabbit kidney. Prostaglandins. 1980 Jul;20(1):111–125. doi: 10.1016/0090-6980(80)90011-8. [DOI] [PubMed] [Google Scholar]
  63. Kuehl F. A., Jr, Egan R. W. Prostaglandins, arachidonic acid, and inflammation. Science. 1980 Nov 28;210(4473):978–984. doi: 10.1126/science.6254151. [DOI] [PubMed] [Google Scholar]
  64. Kvietys P. R., Smith S. M., Grisham M. B., Manci E. A. 5-Aminosalicylic acid protects against ischemia/reperfusion-induced gastric bleeding in the rat. Gastroenterology. 1988 Mar;94(3):733–738. doi: 10.1016/0016-5085(88)90247-8. [DOI] [PubMed] [Google Scholar]
  65. LENNARD-JONES J. E., MISIEWICZ J. J., CONNELL A. M., BARON J. H., JONES F. A. PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION. Lancet. 1965 Jan 23;1(7378):188–189. doi: 10.1016/s0140-6736(65)90973-6. [DOI] [PubMed] [Google Scholar]
  66. Lauritsen K., Hansen J., Bytzer P., Bukhave K., Rask-Madsen J. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut. 1984 Nov;25(11):1271–1278. doi: 10.1136/gut.25.11.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Lauritsen K., Laursen L. S., Bukhave K., Rask-Madsen J. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut. 1988 Oct;29(10):1316–1321. doi: 10.1136/gut.29.10.1316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Lauritsen K., Staerk Laursen L., Bukhave K., Rask-Madsen J. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut. 1988 Jul;29(7):974–982. doi: 10.1136/gut.29.7.974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Laursen L. S., Naesdal J., Bukhave K., Lauritsen K., Rask-Madsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet. 1990 Mar 24;335(8691):683–685. doi: 10.1016/0140-6736(90)90803-d. [DOI] [PubMed] [Google Scholar]
  70. Laursen M. L. The influence of salicyl-azo-sulfapyridine on the immune response to antigenic tumour cells inoculated into the coecal lumen of C3H mice. Scand J Gastroenterol. 1978;13(8):991–997. doi: 10.3109/00365527809181381. [DOI] [PubMed] [Google Scholar]
  71. Ligumsky M., Karmeli F., Sharon P., Zor U., Cohen F., Rachmilewitz D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology. 1981 Sep;81(3):444–449. [PubMed] [Google Scholar]
  72. Lin Y. M., Jarabak J. Isolation of two proteins with 9-ketoprostaglandin reductase and NADP-linked 15-hydroxyprostaglandin dehydrogenase activities and studies on their inhibition. Biochem Biophys Res Commun. 1978 Apr 28;81(4):1227–1234. doi: 10.1016/0006-291x(78)91267-6. [DOI] [PubMed] [Google Scholar]
  73. MacDermott R. P., Kane M. G., Steele L. L., Stenson W. F. Inhibition of cytotoxicity by sulfasalazine. I. Sulfasalazine inhibits spontaneous cell-mediated cytotoxicity by peripheral blood and intestinal mononuclear cells from control and inflammatory bowel disease patients. Immunopharmacology. 1986 Apr;11(2):101–109. doi: 10.1016/0162-3109(86)90030-5. [DOI] [PubMed] [Google Scholar]
  74. MacDermott R. P., Schloemann S. R., Bertovich M. J., Nash G. S., Peters M., Stenson W. F. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology. 1989 Feb;96(2 Pt 1):442–448. doi: 10.1016/0016-5085(89)91569-2. [DOI] [PubMed] [Google Scholar]
  75. Mahida Y. R., Lamming C. E., Gallagher A., Hawthorne A. B., Hawkey C. J. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 1991 Jan;32(1):50–54. doi: 10.1136/gut.32.1.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Marcinkiewicz E., Duniec Z., Robak J. Salazosulfapyridine and non-steroidal antiinflammatory drugs do not inhibit soybean lipoxygenase. Biochem Pharmacol. 1985 Jan 1;34(1):148–149. doi: 10.1016/0006-2952(85)90115-7. [DOI] [PubMed] [Google Scholar]
  77. McConkey B., Amos R. S., Butler E. P., Crockson R. A., Crockson A. P., Walsh L. Salazopyrin in rheumatoid arthritis. Agents Actions. 1978 Jun;8(4):438–441. doi: 10.1007/BF01968673. [DOI] [PubMed] [Google Scholar]
  78. Miyachi Y., Yoshioka A., Imamura S., Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut. 1987 Feb;28(2):190–195. doi: 10.1136/gut.28.2.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Moldéus P., Ross D., Larsson R. Co-oxidation of xenobiotics. Biochem Soc Trans. 1985 Oct;13(5):847–850. doi: 10.1042/bst0130847. [DOI] [PubMed] [Google Scholar]
  80. Molin L., Stendahl O. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand. 1979;206(6):451–457. doi: 10.1111/j.0954-6820.1979.tb13545.x. [DOI] [PubMed] [Google Scholar]
  81. Moore P. K., Hoult J. R. Selective actions of aspirin- and sulphasalazine-like drugs against prostaglandin synthesis and breakdown. Biochem Pharmacol. 1982 Mar 15;31(6):969–971. doi: 10.1016/0006-2952(82)90329-x. [DOI] [PubMed] [Google Scholar]
  82. Neal T. M., Winterbourn C. C., Vissers M. C. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine. Biochem Pharmacol. 1987 Sep 1;36(17):2765–2768. doi: 10.1016/0006-2952(87)90262-0. [DOI] [PubMed] [Google Scholar]
  83. Neumann V. C., Grindulis K. A., Hubball S., McConkey B., Wright V. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1099–1102. doi: 10.1136/bmj.287.6399.1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Neumann V. C., Grindulis K. A. Sulphasalazine in rheumatoid arthritis: an old drug revived. J R Soc Med. 1984 Mar;77(3):169–172. doi: 10.1177/014107688407700301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Neumann V. C., Taggart A. J., Le Gallez P., Astbury C., Hill J., Bird H. A. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J Rheumatol. 1986 Apr;13(2):285–287. [PubMed] [Google Scholar]
  86. Nielsen O. H., Ahnfelt-Rønne I. 4-Aminosalicylic acid, in contrast to 5-aminosalicylic acid, has no effect on arachidonic acid metabolism in human neutrophils, or on the free radical 1,1-diphenyl-2-picrylhydrazyl. Pharmacol Toxicol. 1988 Apr;62(4):223–226. doi: 10.1111/j.1600-0773.1988.tb01876.x. [DOI] [PubMed] [Google Scholar]
  87. Nielsen O. H., Bukhave K., Elmgreen J., Ahnfelt-Rønne I. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577–582. doi: 10.1007/BF01296156. [DOI] [PubMed] [Google Scholar]
  88. Nielsen O. H., Verspaget H. W., Elmgreen J. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment Pharmacol Ther. 1988 Jun;2(3):203–211. doi: 10.1111/j.1365-2036.1988.tb00689.x. [DOI] [PubMed] [Google Scholar]
  89. Nielsen S. T., Beninati L., Buonato C. B. Sulfasalazine and 5-aminosalicylic acid inhibit contractile leukotriene formation. Scand J Gastroenterol. 1988 Apr;23(3):272–276. doi: 10.3109/00365528809093864. [DOI] [PubMed] [Google Scholar]
  90. Nishida T., Miwa H., Shigematsu A., Yamamoto M., Iida M., Fujishima M. Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. Gut. 1987 Aug;28(8):1002–1007. doi: 10.1136/gut.28.8.1002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Ogle C. W., Cho C. H. Effects of sulphasalazine on stress ulceration and mast cell degranulation in rat stomach. Eur J Pharmacol. 1985 Jun 7;112(2):285–286. doi: 10.1016/0014-2999(85)90512-6. [DOI] [PubMed] [Google Scholar]
  92. Pacheco S., Hillier K., Smith C. Increased arachidonic acid levels in phospholipids of human colonic mucosa in inflammatory bowel disease. Clin Sci (Lond) 1987 Oct;73(4):361–364. doi: 10.1042/cs0730361. [DOI] [PubMed] [Google Scholar]
  93. Panganamala R. V., Sharma H. M., Heikkila R. E., Geer J. C., Cornwell D. G. Role of hydroxyl radical scavengers dimethyl sulfoxide, alcohols and methional in the inhibition of prostaglandin biosynthesis. Prostaglandins. 1976 Apr;11(4):599–607. doi: 10.1016/0090-6980(76)90063-0. [DOI] [PubMed] [Google Scholar]
  94. Pekoe G., Van Dyke K., Mengoli H., Peden D., English D. Comparison of the effects of antioxidant non-steroidal anti-inflammatory drugs against myeloperoxidase and hypochlorous acid luminol-enhanced chemiluminescence. Agents Actions. 1982 Apr;12(1-2):232–238. doi: 10.1007/BF01965152. [DOI] [PubMed] [Google Scholar]
  95. Peskar B. M., Dreyling K. W., May B., Schaarschmidt K., Goebell H. Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci. 1987 Dec;32(12 Suppl):51S–56S. doi: 10.1007/BF01312464. [DOI] [PubMed] [Google Scholar]
  96. Peskar B. M., Dreyling K. W., Peskar B. A., May B., Goebell H. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions. 1986 Jun;18(3-4):381–383. doi: 10.1007/BF01965001. [DOI] [PubMed] [Google Scholar]
  97. Pirmohamed M., Coleman M. D., Hussain F., Breckenridge A. M., Park B. K. Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. Br J Clin Pharmacol. 1991 Sep;32(3):303–310. doi: 10.1111/j.1365-2125.1991.tb03903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Psaila J. V., Myers B., Jones I. R., Rhodes J. Effect of prostaglandin PGE2 on alcohol-induced ulceration in the rat colon. Digestion. 1986;35(4):224–228. doi: 10.1159/000199372. [DOI] [PubMed] [Google Scholar]
  99. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1102–1104. doi: 10.1136/bmj.287.6399.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Pullar T., Hunter J. A., Capell H. A. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed) 1985 May 25;290(6481):1535–1538. doi: 10.1136/bmj.290.6481.1535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Rachmilewitz D., Ligumsky M., Haimovitz A., Treves A. J. Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory diseases of the bowel. Gastroenterology. 1982 Apr;82(4):673–679. [PubMed] [Google Scholar]
  102. Rampton D. S., McNeil N. I., Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut. 1983 Mar;24(3):187–189. doi: 10.1136/gut.24.3.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Rampton D. S., Sladen G. E. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins. 1981 Mar;21(3):417–425. doi: 10.1016/0090-6980(81)90087-3. [DOI] [PubMed] [Google Scholar]
  104. Rampton D. S., Sladen G. E. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J. 1981 May;57(667):297–299. doi: 10.1136/pgmj.57.667.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Rampton D. S., Sladen G. E., Youlten L. J. Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis. Gut. 1980 Jul;21(7):591–596. doi: 10.1136/gut.21.7.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Rhodes J. M., Bartholomew T. C., Jewell D. P. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut. 1981 Aug;22(8):642–647. doi: 10.1136/gut.22.8.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Robert A., Bundy G. L., Field S. O., Nezamis J. E., Davis J. P., Hanchar A. J., Lancaster C., Ruwart M. J. Prevention of cecitis in hamsters by certain prostaglandins. Prostaglandins. 1985 Jun;29(6):961–980. doi: 10.1016/0090-6980(85)90221-7. [DOI] [PubMed] [Google Scholar]
  108. Schiavon R., Freeman G. E., Guidi G. C., Perona G., Zatti M., Kakkar V. V. Selenium enhances prostacyclin production by cultured endothelial cells: possible explanation for increased bleeding times in volunteers taking selenium as a dietary supplement. Thromb Res. 1984 Jun 1;34(5):389–396. doi: 10.1016/0049-3848(84)90243-3. [DOI] [PubMed] [Google Scholar]
  109. Schlenker T., Peskar B. M. Dual effect of sulphasalazine on colonic prostaglandin synthetase. Lancet. 1981 Oct 10;2(8250):815–815. doi: 10.1016/s0140-6736(81)90235-x. [DOI] [PubMed] [Google Scholar]
  110. Schreiber S., MacDermott R. P., Raedler A., Pinnau R., Bertovich M. J., Nash G. S. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology. 1991 Oct;101(4):1020–1030. doi: 10.1016/0016-5085(91)90729-5. [DOI] [PubMed] [Google Scholar]
  111. Shanahan F., Niederlehner A., Carramanzana N., Anton P. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology. 1990 Nov-Dec;20(3):217–224. doi: 10.1016/0162-3109(90)90037-f. [DOI] [PubMed] [Google Scholar]
  112. Sharon P., Ligumsky M., Rachmilewitz D., Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978 Oct;75(4):638–640. [PubMed] [Google Scholar]
  113. Sharon P., Stenson W. F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984 Mar;86(3):453–460. [PubMed] [Google Scholar]
  114. Sheldon P., Webb C., Grindulis K. A. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action? Br J Rheumatol. 1988 Oct;27(5):344–349. doi: 10.1093/rheumatology/27.5.344. [DOI] [PubMed] [Google Scholar]
  115. Sinclair R. J., Duthie J. J. Salazopyrin in the Treatment of Rheumatoid Arthritis. Ann Rheum Dis. 1949 Sep;8(3):226–231. doi: 10.1136/ard.8.3.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Sircar J. C., Schwender C. F., Carethers M. E. Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170–172. doi: 10.1016/0006-2952(83)90673-1. [DOI] [PubMed] [Google Scholar]
  117. Smith P. R., Dawson D. J., Swan C. H. Prostaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate and prednisolone. Gut. 1979 Sep;20(9):802–805. doi: 10.1136/gut.20.9.802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Stenson W. F., Lobos E. Inhibition of platelet thromboxane synthetase by sulfasalazine. Biochem Pharmacol. 1983 Jul 15;32(14):2205–2209. doi: 10.1016/0006-2952(83)90227-7. [DOI] [PubMed] [Google Scholar]
  119. Stenson W. F., Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982 Feb;69(2):494–497. doi: 10.1172/JCI110474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Stenson W. F., Mehta J., Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol. 1984 Feb 1;33(3):407–412. doi: 10.1016/0006-2952(84)90233-8. [DOI] [PubMed] [Google Scholar]
  121. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol. 1988 May;83(5):497–503. [PubMed] [Google Scholar]
  122. Svartz N. Treatment of ulcerative colitis with salazopyrin. Int Surg. 1968 Nov;50(5):421–427. [PubMed] [Google Scholar]
  123. Symmons D. P., Salmon M., Farr M., Bacon P. A. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. J Rheumatol. 1988 Apr;15(4):575–579. [PubMed] [Google Scholar]
  124. Thayer W. R., Jr, Charland C., Field C. E. Effects of sulfasalazine on selected lymphocyte subpopulations in vivo and in vitro. Dig Dis Sci. 1979 Sep;24(9):672–679. doi: 10.1007/BF01314463. [DOI] [PubMed] [Google Scholar]
  125. Vilaseca J., Salas A., Guarner F., Rodriguez R., Malagelada J. R. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology. 1990 Feb;98(2):269–277. doi: 10.1016/0016-5085(90)90814-h. [DOI] [PubMed] [Google Scholar]
  126. Wallace J. L., MacNaughton W. K., Morris G. P., Beck P. L. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology. 1989 Jan;96(1):29–36. doi: 10.1016/0016-5085(89)90760-9. [DOI] [PubMed] [Google Scholar]
  127. Wallace J. L., Whittle B. J., Boughton-Smith N. K. Prostaglandin protection of rat colonic mucosa from damage induced by ethanol. Dig Dis Sci. 1985 Sep;30(9):866–876. doi: 10.1007/BF01309518. [DOI] [PubMed] [Google Scholar]
  128. Wanders A., Tufveson G., Gerdin B. The enhancing effect of cyclosporine A and sulfasalazine on the prevention of rejection in rat cardiac allografts. Transpl Int. 1988 Jul;1(2):113–115. doi: 10.1007/BF00353831. [DOI] [PubMed] [Google Scholar]
  129. Williams J. G., Hallett M. B. Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils. Gut. 1989 Nov;30(11):1581–1587. doi: 10.1136/gut.30.11.1581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Yamada T., Volkmer C., Grisham M. B. The effects of sulfasalazine metabolites on hemoglobin-catalyzed lipid peroxidation. Free Radic Biol Med. 1991;10(1):41–49. doi: 10.1016/0891-5849(91)90020-4. [DOI] [PubMed] [Google Scholar]
  131. Zipser R. D., Nast C. C., Lee M., Kao H. W., Duke R. In vivo production of leukotriene B4 and leukotriene C4 in rabbit colitis. Relationship to inflammation. Gastroenterology. 1987 Jan;92(1):33–39. doi: 10.1016/0016-5085(87)90836-5. [DOI] [PubMed] [Google Scholar]
  132. von Ritter C., Grisham M. B., Granger D. N. Sulfasalazine metabolites and dapsone attenuate formyl-methionyl-leucyl-phenylalanine-induced mucosal injury in rat ileum. Gastroenterology. 1989 Mar;96(3):811–816. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES